A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

Purpose The optimal duration of post-radiation temozolomide in newly diagnosed glioblastoma remains unclear, with no published phase III randomised trials. Standard-of-care stipulates 6 months. However, in routine care, it is often extended to 12 months, despite lacking robust supporting data. Metho...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neuro-oncology 2024-02, Vol.166 (3), p.407-415
Hauptverfasser:	Gately, L., Mesía, C., Sepúlveda, J. M., del Barco, S., Pineda, E., Gironés, R., Fuster, J., Hong, W., Dumas, M., Gill, S., Navarro, L. M., Herrero, A., Dowling, A., de las Peñas, R., Vaz, M. A., Alonso, M., Lwin, Z., Harrup, R., Peralta, S., Long, A., Perez-Segura, P., Ahern, E., Garate, C. O., Wong, M., Campbell, R., Cuff, K., Jennens, R., Gallego, O., Underhill, C., Martinez-Garcia, M., Covela, M., Cooper, A., Brown, S., Rosenthal, M., Torres, J., Collins, I. M., Gibbs, P., Balana, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Alkylating - adverse effects Brain cancer Brain Neoplasms - drug therapy Brain Neoplasms - radiotherapy Clinical trials Dacarbazine - adverse effects Disease-Free Survival Glioblastoma Glioblastoma - drug therapy Glioblastoma - radiotherapy Humans Medicine Medicine & Public Health Neurology Oncology Post-radiation Prospective Studies Radiation Survival Temozolomide Temozolomide - therapeutic use Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!